**Supplementary Table 1: Generic names and brand names of taxanes.**

|  |  |
| --- | --- |
| **Generic name** | **Brand name** |
| Paclitaxel | Taxol |
| Paxane |
| Onxol |
| Docetaxel | Taxotere |
| Docetaxel accord |
| Docetaxel anhydrous |
| Docetaxel kabi |
| Docetaxel mylan |
| Docetaxel pharma |
| Taxespira |
| Albumin-bound paclitaxel | Nab-paclitaxel |
| Abraxane |

**Supplementary Table 2: Taxane-asscociated adverse events and preferred terms.**

|  |  |  |
| --- | --- | --- |
| **Adverse events** | **MedDRA code** | **PTs** |
| Hypersensitivity reaction | 10046735 | Urticaria |
| 10037844 | Rash |
| 10016825 | Flushing |
| 10002424 | Angioedema |
| 10037087 | Pruritus |
| 10006482 | Bronchospasm |
| 10013968 | Dyspnea |
| 10008531 | Chills |
| 10008479 | Chest pain |
| 10047700 | Vomiting |
| 10028411 | Myalgia |
| 10003239 | Arthralgia |
| 10040560 | Shock |
| 10002198 | Anaphylactic reaction |
| Bone marrow toxicity | 10051779 | Bone marrow toxicity |
| 10029354 | Neutropenia |
| 10024384 | Leukopenia |
| 10002034 | Anemia |
| 10025327 | Lymphopenia |
| 10043554 | Thrombocytopenia |
| Neuropathy peripheral | 10029331 | Neuropathy peripheral |
| 10034620 | Peripheral sensory neuropathy |

PTs: Preferred terms.

**Supplementary Table 3: Summary of major algorithms used for signal detection.**

|  |  |  |
| --- | --- | --- |
| **Algorithms** | **Equation** | **Criteria** |
| ROR | ROR = (a/b)/(c/d)  95% CI = eln(ROR) ± 1.96(1/a + 1/b + 1/c + 1/d)^0.5 | 95% CI > 1, *N* ≥ 2 |
| PRR | PRR = (a/(a + c))/(b/(b + d))  χ2 = Σ((O-E)2/E); (O = a, E = (a + b)(a + c)/(a + b + c + d)) | PRR ≥ 2, χ2 ≥ 4, *N* ≥ 3 |
| BCPNN | IC = log2a(a + b + c + d)/((a + c)(a + b))  IC025 = eln(IC)−1.96(1/a + 1/b + 1/c + 1/d)^0.5 | IC025 > 0 |
| MGPS | EBGM = a(a + b + c + d)/((a + c)(a + b))  EBGM05 = eln(EBGM)−1.64(1/a + 1/b + 1/c + 1/d)^0.5 | EBGM05 > 2, *N* > 0 |

Equation: a, number of reports containing both the suspect drug and the suspect adverse drug reaction; b, number of reports containing the suspect adverse drug reaction with other medications (except the drug of interest); c, number of reports containing the suspect drug with other adverse drug reactions (except the event of interest); d, number of reports containing other medications and other adverse drug reactions.

BCPNN: Bayesian confidence propagation neural network; CI: Confidence interval; EBGM: Empirical Bayesian geometric mean; EBGM05: The lower 95% one-sided CI of EBGM; IC: Information component; IC025: The lower limit of the 95% two-sided CI of the IC; MGPS: Multi-item gamma Poisson shrinker; *N*: The number of co-occurrences; PRR: Proportional reporting ratio; ROR: Reporting odds ratio.